Use of cd44v6 in the treatment of ophthalmic diseases

Abstract

The present invention relates to the use of peptide compounds for the prevention and/or treatment of ophthalmic diseases. In particular, the present invention relates to a peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 (KEQWFGNRWHEGYR) or of SEQ ID NO: 1 (KEKWFENEWQGKNP), or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatmend of an ophthalmic disease in an individual. While SEQ ID NO: 2 is a part of the human CD44v6, SEQ ID NO: 1 is a part of the rat CD44v6.

1 . A peptide compound comprising an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 or of SEQ ID NO: 1, or a functionally active derivative thereof, or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The peptide compound according to  claim 1 , wherein the peptide compound comprises SEQ ID NO: 2. 
     
     
         3 . The peptide compound according to  claim 1 , wherein the peptide compound comprises SEQ ID NO: 1. 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . The peptide compound according to  claim 1 , wherein the peptide compound comprises an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO:2. 
     
     
         9 . The peptide compound according to  claim 1 , wherein the peptide compound comprises an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 1. 
     
     
         10 . The peptide compound according to  claim 1 , wherein the peptide compound is a cyclopeptide or a pharmaceutically acceptable salt thereof. 
     
     
         11 . A method for preventing or treating an ophthalmic disease in an individual, the method comprising administering to an individual an effective amount of a peptide compound of  claim 1 . 
     
     
         12 . The method according to  claim 11 , wherein the peptide compound comprises SEQ ID NO: 2. 
     
     
         13 . The method according to  claim 11 , wherein the peptide compound comprises SEQ ID NO: 1. 
     
     
         14 . The method according to  claim 11 , wherein the ophthalmic disease is associated with overexpression of VEGFR-2. 
     
     
         15 . The method according to  claim 11 , wherein the ophthalmic disease is associated with hyperproliferation of endothelial cells. 
     
     
         16 . The method according to  claim 11 , wherein the ophthalmic disease is macular degeneration or diabetic retinopathy. 
     
     
         17 . The method according to  claim 11 , wherein the individual is a mammal 
     
     
         18 . The method according to  claim 11 , wherein the peptide compound comprises an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 2 and the individual is a human. 
     
     
         19 . The method according to  claim 11 , wherein the peptide compound comprises an amino acid sequence displayed by amino acids 7 to 11 of SEQ ID NO: 1 and the individual is a rat. 
     
     
         20 . The method according to  claim 11 , wherein the peptide compound is a cyclopeptide or a pharmaceutically acceptable salt thereof.